Chromocell Therapeutics (CHRO) Stock Price, News & Analysis

Company Overview

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.

Key Stats

• Today's Range: $1.23 to $1.48
• 50-Day Range: $1.34 to $13.50
• 52-Week Range: $4.50 to $38.00
• Volume: 194,032 shs
• Average Volume: 47,337 shs
• Market Capitalization: $8.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CHRO Stock Analysis - Frequently Asked Questions

When did Chromocell Therapeutics' stock split?

Chromocell Therapeutics shares reverse split on Wednesday, July 2nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Chromocell Therapeutics IPO?

Chromocell Therapeutics (CHRO) raised $7 million in an IPO on Friday, February 16th 2024. The company issued 1,100,000 shares at $6.00 per share.

Company Calendar

• Today: 9/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CHRO
• Previous Symbol: NYSE:CHRO
• CIK: 1919246
• Web: chromocell.com
• Phone: 732-514-2636
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -453.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.65) per share
• Price / Book: -0.81

Miscellaneous

• Outstanding Shares: 6,485,000
• Free Float: 5,039,000
• Market Cap: $8.69 million
• Optionable: N/A
• Beta: 3.63